Title:
COLD ANTI-CD20 ANTIBODY/RADIOLABELED ANTI-CD22 ANTIBODY COMBINATION
Document Type and Number:
WIPO Patent Application WO2001097858
Kind Code:
A3
Abstract:
Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN3 and a radiolabeled anti-CD22 antibody, preferably an <90>Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN3 and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
Inventors:
WHITE CHRISTINE
Application Number:
PCT/US2001/018939
Publication Date:
August 08, 2002
Filing Date:
June 14, 2001
Export Citation:
Assignee:
IDEC PHARMA CORP (US)
International Classes:
A61K51/00; A61K39/395; A61K51/10; A61P35/00; A61P35/02; A61P37/06; A61P37/08; A61P43/00; (IPC1-7): A61K51/10; A61K47/48; A61P35/00
Domestic Patent References:
| WO1998042378A1 | 1998-10-01 | |||
| WO2000020864A1 | 2000-04-13 | |||
| WO2000074718A1 | 2000-12-14 | |||
| WO2001010461A1 | 2001-02-15 | |||
| WO2000067796A1 | 2000-11-16 | |||
| WO2002022212A2 | 2002-03-21 | |||
| WO2002004021A1 | 2002-01-17 |
Foreign References:
| US5789554A | 1998-08-04 | |||
| US6090365A | 2000-07-18 |
Other References:
See also references of EP 1299128A2
Download PDF:
Previous Patent: AN ORPHAN NUCLEAR RECEPTOR
Next Patent: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY
Next Patent: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY